(Q28263634)

The Sequence of the Human Genome

21 April 2017

1 reference

Mutations of the BRAF gene in human cancer

21 April 2017

1 reference

Mutational analysis of the tyrosine kinome in colorectal cancers

21 April 2017

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

21 April 2017

1 reference

Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation

21 April 2017

1 reference

1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis

21 April 2017

1 reference

21 April 2017

1 reference

Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients

21 April 2017

1 reference

End-sequence profiling: sequence-based analysis of aberrant genomes

21 April 2017

1 reference

A census of human cancer genes

21 April 2017

1 reference

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 April 2017

1 reference

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 April 2017

1 reference

Expression profiling predicts outcome in breast cancer

21 April 2017

1 reference

A gene-expression signature as a predictor of survival in breast cancer

21 April 2017

1 reference

Complete sequencing and characterization of 21,243 full-length human cDNAs

21 April 2017

1 reference

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

21 April 2017

1 reference

Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences

21 April 2017

1 reference

NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate

21 April 2017

1 reference

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 April 2017

1 reference

From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes

21 April 2017

1 reference

Biodiversity hotspots for conservation priorities

21 April 2017

1 reference

A molecular signature of metastasis in primary solid tumors

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

The genetics and genomics of cancer

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Comprehensive genetic analysis of cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

STI571 (Gleevec) as a paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Targeted therapies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Beyond Herceptin and Gleevec

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

High-resolution analysis of genetic events in cancer cells using bacterial artificial chromosome arrays and comparative genome hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

DNA methylation differences associated with tumor tissues identified by genome scanning analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

A real-time PCR assay for DNA-methylation using methylation-specific blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

The UMD-p53 database: new mutations and analysis tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Identifying distinct classes of bladder carcinoma using microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Serial analysis of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

An international database and integrated analysis tools for the study of cancer gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Using the transcriptome to annotate the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Increase of functional diversity by alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Sequence-based cancer genomics: progress, lessons and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Receptor tyrosine kinases: the main targets for new anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Signal transduction--directed cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Small molecule inhibitors of the class 1 receptor tyrosine kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

BAY 43-9006: preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Imatinib mesylate in the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Imatinib alone and in combination for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Management of malignant gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

PRAC2: A new gene expressed in human prostate and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Identification of cancer/testis genes by database mining and mRNA expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Cancer vaccines entering Phase III clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Antigen-specific immunotherapy and cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Targeting of radio-isotopes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Potential clinical application of antioncogene ribozymes for human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Use of isogenic human cancer cells for high-throughput screening and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Medicine. The NIH Roadmap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

The Human Genome Project: Lessons from Large-Scale Biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Natural products as sources of new drugs over the period 1981-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

The FLEXGene repository: exploiting the fruits of the genome projects by creating a needed resource to face the challenges of the post-genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Antibody discovery: phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

New technologies in therapeutic antibody development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Organ targeting in vivo using phage display peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Anti-cancer activity of targeted pro-apoptotic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

inferred from DOI database lookup

7 January 2021

based on heuristic

Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627

inferred from DOI database lookup

7 January 2021

based on heuristic

Attrition and Translation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02627